Table 1.

Systemic Therapeutic Options for Three Major Breast Cancer Subtypes

	Luminal A/B	HER2-Enriched	Triple-Negative	References
Endocrine Therapy -Selective estrogen-receptor modulators (SERMs; eg, tamoxifen) -Aromatase inhibitors (AIs; eg, exemestane, anastrozole and letrozole)	-Used in all patients	-Used only in patients with HR-positive breast tumours	-N/A	[13]
HER2-targeted Therapy -Trastuzumab ± pertuzumab	-N/A	-Used in all patients	-N/A	[13]
Chemotherapy -Cyclophosphamide + methotrexate + 5-fluorouracil (CMF) -Doxorubicin + cyclophosphamide (AC) -5-Fluorouracil + epirubicin + cyclophosphamide (FEC) -Cyclophosphamide + doxorubicin + 5-flurouracil (CAF or FAC) -Doxorubicin + cyclophosphamide + paclitaxel (AC-T) -Docetaxel + cyclophosphamide (TC)	-Used only in some patients	-Used in all patients	-Used in all patients	[12,13]